The DICIPLE (Double Immune Checkpoint Inhibitors in PD-L1–Positive Stage IV NSCLC [ClinicalTrials.gov identifier: NCT03469960]) phase 3 clinical trial of patients with advanced NSCLC will further assess issues regarding nivolumab-ipilimumab treatment duration. Here, CD274 is linked to non-small cell lung carcinoma.